| MOST COMMON ADVERSE REACTIONS1 (≥2%, POOLED SAFETY DATA ACROSS PRIME AND PRIME2) |
||
|---|---|---|
| ADVERSE REACTION | DUPIXENT 300 mg Q2W (n=152) % |
PLACEBO (n=157) % |
| Nasopharyngitisa | 5 | 2 |
| Conjunctivitisb | 4 | 1 |
| Herpes Infectionc | 3 | 0 |
| Dizzinessd | 3 | 1 |
| Myalgiae | 3 | 1 |
| Diarrhea | 3 | 1 |
aNasopharyngitis includes pharyngitis.
bConjunctivitis includes conjunctivitis and allergic conjunctivitis.
cHerpes infection includes oral herpes, genital herpes simplex, herpes zoster, and ophthalmic herpes zoster.
dDizziness includes dizziness postural, vertigo, and vertigo positional.
eMyalgia includes musculoskeletal pain and musculoskeletal chest pain.
No treatment discontinuation due to adverse events at Week 24Safety profile studied in >9000 patients across US-approved indications1,f
OTHER CONSIDERATIONS
NOT AN IMMUNOSUPPRESSANT
OR A STEROID1
NO INITIAL LAB TESTING OR
ONGOING
LAB MONITORING according to the Prescribing Information1
NO BOXED WARNING1
Please see additional Warnings and
Precautions in the Prescribing
Information
and Important Safety
Information below.
NO KNOWN DRUG-TO-DRUG
INTERACTIONS1
- Not metabolized through the liver or excreted
through the kidneys
SELECT IMPORTANT SAFETY INFORMATION
WARNINGS AND PRECAUTIONS
- Hypersensitivity: Hypersensitivity reactions, including anaphylaxis, acute generalized exanthematous pustulosis (AGEP), serum sickness or serum sickness-like reactions, angioedema, generalized urticaria, rash, erythema nodosum, and erythema multiforme have been reported. A case of AGEP was reported in an adult subject who participated in the bullous pemphigoid development program. If a clinically significant hypersensitivity reaction occurs, institute appropriate therapy and discontinue DUPIXENT.
Please see additional Warnings and Precautions in the Prescribing Information and Important Safety Information below.
- fPatient total included patients in AD trials (SOLO 1, SOLO 2, CHRONOS, AD-1021, AD-1526, AD-1652, AD-1539, and AD-HAFT), asthma trials (DRI12544, QUEST, VENTURE, and VOYAGE), CRSwNP trials (SINUS-24 and SINUS-52), EoE trials (EoE-1 and EoE-2), PN trials (PRIME and PRIME2), COPD trials (BOREAS and NOTUS), CSU trials (CUPID-A, CUPID-B, CUPID-C), and BP trial (ADEPT).1
Dosage and administration
Thinking about prescribing DUPIXENT? Find the
information you need to get started.